Despite significant progress in asthma drug therapy in recent years, there has been no major change in asthma morbidity and mortality. It is still important to determine whether pharmaceutical care (PC) influences health outcomes.
OBJECTIVE
To evaluate the effectiveness of PC with regard to clinical, humanistic, and economic outcomes in adults with asthma.
METHODS
An intervention study was conducted over 12 months. At baseline, 39 community/retail pharmacies, 84 primary care physicians (general practitioners, internal specialists, chest physicians), and 183 patients (aged 18–65 y) diagnosed with asthma were included. To evaluate economic outcomes, 2 German statutory health insurance funds provided 2 years of claims data for their insured patients (n = 55). A 1:10 matching was carried out to compare the data of this intervention subgroup with those of a control group (n = 550).
RESULTS
Significant improvements were found for all humanistic outcomes (eg, asthma-specific quality of life, self-efficacy, knowledge, medication adherence). In addition, asthma severity, self-reported symptoms, peak expiratory flow, and patients’ inhalation technique improved. Increases in forced expiratory volume in 1 second and vital capacity were not significant over time. Evaluation of the insurance claims data revealed a shift toward better adherence to evidence-based therapy.
CONCLUSIONS
The study shows that PC for people with asthma has a positive impact on humanistic and, to some extent, on clinical outcomes. To determine potential economic benefits, future research should focus on patients with more severe asthma.
. MathersCD, BernardC, Moesgaard IburgK, InoueM, FatDM, ShibuyaK, Global programme on evidence for health policy. Discussion paper no. 54. In: Global burden of disease in 2002: data sources, methods and results. Geneva: World Health Organisation, 2003.
2.
. RabeK, AdachiM, LaiC, SorianoJ, VermeireP, WeissK, Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol2004; 114: 40–7.
3.
. StockS, RedaelliM, LuengenM, WendlandG, CivelloD, LauterbachKW. Asthma: prevalence and cost of illness. Eur Respir J2005; 25: 47–53.
4.
. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report (updated 2003). Washington, DC: National Institutes of Health, 2002. NIH publication no. 02–3659.
5.
. WettengelR, VolmerT. Asthma—Medizinische und ókonomische Bedeutung einer Volkskrankheit. Stuttgart: Norbert Rupp, 1994: 60.
6.
. KolbeJ, VamosM, JamesF, ElkindG, GarretJ. Assessment of practical knowledge of self-management of acute asthma. Chest1996; 109: 86–90.
7.
. BarnesPJ, JonssonB, KlimJB. The cost of asthma. Eur Respir J1996; 9: 636–42.
8.
. SudreP, JacquementS, UldryC, PernegerTV. Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998. Thorax1999; 54: 681–7.
9.
. HaahtelaT. The disease management approach to controlling asthma. Respir Med2002; 96 (suppl A): S1–8.
10.
. CordinaM, McElnayJC, HughesCM. Assessment of a community pharmacy–based program for patients with asthma. Pharmacotherapy2001; 21: 1196–203.
11.
. HerborgH, SoendergaardB, FroekjaerB, FonnesbaekL, JorgensenT, HeplerCD, Improving drug therapy for patients with asthma—part 1. Patient outcomes. J Am Pharm Assoc2001; 41: 539–50.
12.
. HerborgH, SoendergaardB, JorgensenT, FonnesbaekL, HeplerCD, HolstH, Improving drug therapy for patients with asthma—part 2. Use of anti-asthma medications. J Am Pharm Assoc2001; 41: 551–9.
13.
. NärhiU, AiraksinenM, TanskanenP, EnlundH. The effects of a pharmacy-based intervention on the knowledge and attitudes of asthma patients. Patient Educ Couns2001; 43: 171–7.
14.
. SchulzM, VerheyenF, MúhligS, MúllerJM, MúhlbauerK, Knop-SchneickertE, Pharmaceutical care services for asthma patients. A controlled intervention study. J Clin Pharmacol2001; 41: 668–76.
15.
. SainiB, KrassI, ArmourC. Development, implementation and evaluation of a community pharmacy–based asthma care model. Ann Pharmacother2004; 38: 1954–60. Epub 12 Oct 2004. DOI 10.1345/aph.1E045
16.
. McLeanW, WallerR, GillisJ. The BC community pharmacy asthma study: a study of clinical, economic, and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J2003; 10: 195–202.
17.
. WeinbergerM, MurrayMD, MarreroDG, BrewerN, LykensM, HarrisLE, Effectiveness of pharmacist care for patients with reactive airway disease—a randomized controlled trial. JAMA2002; 288: 1594–602.
18.
. Wahner-RoedlerDL, KnuthP, JuchemsRH. The German health-care system. Mayo Clin Proc1997; 72: 1061–8.
. StrandLM, CipolleRJ, MorleyPC. Pharmaceutical care: an introduction. Current concepts. Kalamazoo, MI: Upjohn, March 1992.
21.
. McLeanWM, MacKeiganLD. When does pharmaceutical care impact health outcomes? A comparison of community pharmacy–based studies of pharmaceutical care for patients with asthma. Ann Pharmacother2005; 39: 625–31. Epub 1 Mar 2005. DOI 10.1345/aph.1E474
22.
. WettengelR, BerdelD, HofmannD. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie1998; 52: 591–601.
23.
. HylandME, FinnisS, IrvineSH. A scale for assessing quality of life in adult asthma sufferers. J Psychosom Res1991; 35: 99–110.
24.
. MühligS, BergmannKC, EmmermannA, PetermannF. Der Fragebogen zur Lebensqualitát bei Asthma (FLA)—Untersuchungen zur Dimensionalitát und Hinweise zur Auswertung. Pneumologie1998; 52: 35–40.
25.
. KrampenG. Fragebogen zur Kompetenz-und Kontrollüberzeugung. Göttingen, Germany: Hogrefe, 1991.
26.
. MoriskyDE, GreenLW, LevineDM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care1986; 24: 67–74.
27.
. LittleRC, MiilkenGA, StroupWW, WolfingerRD. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
28.
. GibsonPG, CoughlanJ, WilsonAJ, AbramsonM, BaumanA, HesleyMJ, Self-management education and regular practitioner review for adults with asthma. Cochrane Library1999; 3: 1–43.
29.
. van der PalenJ, KleinJJ, SeydelER. Are high generalised and asthma-specific self-efficacy predictive of adequate self-management behaviour among adult asthma patients?Patient Educ Couns1997; 32 (suppl 1): S35–41.
30.
. KolbeJ. Asthma education, action plans, psychosocial issues and adherence. Can Respir J1999; 6: 273–80.
31.
. BellochA, PerpinaM, ParedesT, GiménesA, CompteL, BañosR. Bronchial asthma and personality dimensions: a multifaceted association. J Asthma1994; 31: 161–70.
32.
. SibbaldB, WhiteP, PharoahC, FreelingP, AndersonHR. Relationship between psychosocial factors and asthma morbidity. Fam Pract1998; 5: 12–7.
33.
. EngströmCP, PerssonLO, LarssonS, RydenA, SullivanM. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax1996; 51: 825–30.
34.
. WijkstraPJ, Ten VergertEM, van AltenaR, OttenV, PostmaDS, KraanJ, Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax1994; 49: 465–7.
35.
. MühligS, PetermannF. Messung der Lebensqualität bei Asthma. In: PetermannF, WarschburgerP, eds. Asthma und Allergie. Göttingen, Germany: Hogrefe, 2000; 115–46.
36.
. MelaniAS, ZanchettaD, BarbatoN, SestiniP, CintiC, CanessaPA, for the Associazone Italiana Pneumologi Ospedalieri Educational Group. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol2004; 93: 439–46.
37.
. SchulzM, MúhlbauerK, VerheyenF, Knop-SchneickertE, MúhligS, PetermannF, Pharmaceutical care services for asthma patients (abstract). Eur J Clin Pharmacol1999; 55: A15.
